Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Condition:   Refractory Chronic Cough Interventions:   Drug: 3 mg NOC-100 (via nebulizer);   Drug: 1 mg NOC-110 (via DPI) [1x 1 mg capsule];   Drug: 3 mg NOC-110 (via DPI);   Drug: Placebo (via DPI);   Drug: 6 mg NOC-110 (via DPI);   Drug: Placebo (via DPI) [2x Placebo capsules] Sponsor:   Nocion Therapeutics Completed

Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials